eClinicalMedicine Publication

29th September 2025

Heparin Therapeutics is  pleased to be able to announce that two of its founders were lead and co-author on a recently published paper in a Lancet Group journal showing that inhaled, nebulised UFH is safe and significantly reduces intubation and mortality rates in ca. 500 hospitalised, non-intubated COVID-19 patients. These findings were also presented by our Prof. Frank van Haren at the European Respiratory Society Congress on September 28th 2025.

Please find a link to the article and also some press releases. 

https://authors.elsevier.com/sd/article/S2589-5370(25)00271-8

https://www.kcl.ac.uk/news/low-cost-drug-shows-promise-for-patients-with-life-threating-respiratory-infections

https://reporter.anu.edu.au/all-stories/low-cost-drug-shows-promise-for-patients-with-life-threatening-respiratory-infections